← Back to Search

Monoclonal Antibodies

Risankizumab for Psoriasis (IMMprint Trial)

Phase 3
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (week 0) through 20 weeks after last dose of study drug (up to 60 weeks total)
Awards & highlights

IMMprint Trial Summary

This trial will help study doctors to understand if risankizumab is safe and works well for plaque psoriasis with palmoplantar involvement.

IMMprint Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (week 0) through 20 weeks after last dose of study drug (up to 60 weeks total)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (week 0) through 20 weeks after last dose of study drug (up to 60 weeks total) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with Adverse Events
Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "clear" or "almost clear" (0 or 1) with at least a 2 point reduction from Baseline
Secondary outcome measures
Percentage of Participants Achieving 100% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 100) response
Percentage of Participants Achieving >= 75% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 75) response
Percentage of Participants Achieving >= 90% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 90) response
+1 more

Side effects data

From 2022 Phase 3 trial • 244 Patients • NCT04102007
9%
COVID-19
6%
NASOPHARYNGITIS
1%
OSTEOARTHRITIS
1%
MYOCARDIAL INFARCTION
100%
80%
60%
40%
20%
0%
Study treatment Arm
Risankizumab

IMMprint Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: RisankizumabExperimental Treatment1 Intervention
Participants will receive risankizumab for 52 weeks
Group II: PlaceboPlacebo Group2 Interventions
Participants will receive placebo for 16 weeks followed by risankizumab for 36 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Risankizumab
2021
Completed Phase 3
~3140

Find a Location

Who is running the clinical trial?

AbbVieLead Sponsor
958 Previous Clinical Trials
502,210 Total Patients Enrolled
62 Trials studying Psoriasis
125,438 Patients Enrolled for Psoriasis
ABBVIE INC.Study DirectorAbbVie
397 Previous Clinical Trials
146,924 Total Patients Enrolled
22 Trials studying Psoriasis
17,889 Patients Enrolled for Psoriasis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the government regulations surrounding Risankizumab?

"Since this is a Phase 3 trial, there is already some data affirming Risankizumab's efficacy and multiple rounds of safety data. Therefore, our team at Power rates the safety of Risankizumab as a 3."

Answered by AI

What is the projected sample size for this experiment?

"This study is no longer recruiting patients. The clinical trial was first posted on February 26th, 2021 and the last update to the page was on September 19th, 2022. However, there are many other ongoing studies that might be of interest. For example, there are 179 clinical trials actively searching for participants with psoriasis and 29 studies for Risankizumab actively enrolling participants."

Answered by AI

Risankizumab is most often given to patients for what purpose?

"Risankizumab is most commonly used as a dental plaque treatment, but it can also be effective in treating psoriasis, skin disinfection therapy, and psoriatic arthritis."

Answered by AI

What other medical studies has Risankizumab been a part of in the past?

"Currently, there are 29 ongoing clinical trials for Risankizumab globally. Of these 29 trials, 14 are in Phase 3. Additionally, while several of the clinical trials for Risankizumab originate in Gdansk, Pomorskie, there are 3206 total locations running trials for Risankizumab worldwide."

Answered by AI

Are a lot of these tests being conducted in different hospitals throughout the country?

"43 patients are currently enrolled in this study, with locations including the Center for Clinical Studies - Houston (Binz) /ID# 219221 in Houston, Beacon Dermatology Inc /ID# 220940 in Calgary, and NewLab Clinical Research Inc. /ID# 220934 in St. John's, among others."

Answered by AI

Are there vacancies in this research project for new participants?

"This study is no longer recruiting patients. The original posting date was February 26th, 2021 and the most recent edit occured on September 19th, 2022. However, there are 179 other trials for psoriasis and 29 trials testing Risankizumab that are actively looking for candidates."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
Dr. Chih-ho Hong Medical Inc. /ID# 220941
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
What state do they live in?
Indiana
Recent research and studies
clinicaltrials.govStudy
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
2021. "Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04713592.
~43 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top